Skip to main content
. 2009 Feb;4(2):299–308. doi: 10.2215/CJN.04060808

Table 1.

Clinical data

Characteristic Patient
Case 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Age (years) 57 65 37 39 47 71 50 62 78 79 59 69 51 58
Race White White White Black White White Hispanic Black White White Black White White White
Gender Female Male Female Female Male Male Male Female Male Female Male Male Male Female
ANCA by IIF P-ANCA P-ANCA P-ANCA C-ANCA P-ANCA P-ANCA C-ANCA NA C-ANCA Atypical C-ANCA P-ANCA P-ANCA C-ANCA
ANCA specificity by ELISA MPO NA MPO PR3 MPO MPO PR3 PR3/MPO NA Neg MPO NA NA PR3
Extrarenal manifestations of vasculitis Hemoptysis None None Panuveitis None None Pulmonary nodules None None None None Hemorrhagic duodenitis and GI bleeding Sinusitis and epistaxis Venulitis of liver
Urine protein (g/day) 2 + on UA 5.8 5.5 6.8 14 6.6 0.8 16 Anuria 3 + on UA 3.5 1.9 5.8 5
Serum albumin (g/dl) 3.5 3 2.9 2.3 2.3 3.4 2.5 2.4 2.6 1.4 2.8 2.2 2.9 1.4
Serum creatinine (mg/dl): 2.5 2.2 3.5 1.3 8.6 3 0.9 4.1 4 (on HD) 8.9 6 5.4 8.7 3.1
Treatment IV CY/PRED then MMF PRED/PO CY for 6 mo M-PRED/PRED for 2.3 yrs/ IV CY for 6 mo PRED/PO CY PRED/IV CY for 2 mo PRED/ PO CY for 1 yr Azathioprine for 1 yr before Bx; PRED/PO CY for 1 yr M-PRED then PRED/IV CY for 3 mo PRED/IV CY for 2 mo None PRED/IV CY M-PRED then PRED/PO CY/ PLX NA PRED/ IV then PO CY for 6 mo
Length of follow-up (months) 38 101 28 66 2 46 12 3 4 0.25 4 1 3 8
Follow-up creatinine ESRD Died 1.8 0.9 2.1 ESRD Died 2.8 0.8 ESRD 2.1 Died ESRD 3.5 Died ESRD Died 0.8
Follow-up proteinuria (g/day) ESRD Neg 0.770 4.2 ESRD 0.817 Neg ESRD 0.701 ESRD 1.1 ESRD 1.2

ANCA, antineutrophil cytoplasmic antibody; Bx, biopsy; CY, cyclophosphamide; ELISA, enzyme-linked immunosorbent assay; HD, hemodialysis; IIF, indirect immunofluorescence; MMF, mycophenolate mofetil; MPO, myeloperoxidase; M-PRED, methyl-prednisolone; neg, negative; NA, not available; PLX, plasmapheresis; PO, oral; PR3, proteinase 3; PRED, prednisone; UA, urinalysis.